Longwood Fund
VC Fund
Boston, United States
Longwood Fund is a VC fund in Boston focused on Biotechnology and Therapeutics. Longwood creates and invests in science-based companies that develop novel solutions for important medical problems
- Total investments:
- 77
- Last investment:
- Lead investor:
- 16%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Longwood Fund invests in
Stages Longwood Fund invests in
Countries Longwood Fund invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $16M–$100M
- Series B
- $25M–$152M
- Series C
- $17M–$100M
Investment Focus
Industry
- Biotechnology 38 (49%)
- Therapeutics 19 (25%)
- Health Care 18 (23%)
- Life Science 16 (21%)
- Pharmaceutical 13 (17%)
Stage
- Series A 26 (34%)
- Series B 16 (21%)
- Series C 9 (12%)
- Funding Round 6 (8%)
- Seed 1 (1%)
Country
- United States 39 (51%)
- United Kingdom 3 (4%)
- Italy 1 (1%)
- Belgium 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Aleks Radovic-Moreno
Partner
|
Partner | Total investments: 1 | Find email | |
John McCabe
Operating Partner
|
Operating Partner | Total investments: 0 | Find email | |
Christoph Westphal
Manager
|
Manager | Total investments: 11 | Find email | |
David Donabedian
Executive Partner
|
Executive Partner | Total investments: 2 | Find email | |
David Donabedian, PhD
Venture Partner
|
Venture Partner | Total investments: 1 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Coultreon Biopharma
|
Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.Coultreon Biopharma employs extensive experience in disease biology, drug development, and translational science to identify the optimum treatment approach for addressing underlying illness biology withbest-in-class therapeutics. | $125M / Series A / Apr 28, 2026 | |
Neomorph
|
Neomorph is building a leading protein degradation entity, focused on “molecular glue” degraders. Its mission is to use this technology to solve critical problems in human health with the discovery and development of innovative new medicines against “undruggable targets.” | $100M / Series B / Apr 13, 2026 | |
Sidewinder Therapeutics
|
Sidewinder Therapeutics develops bispecific antibody-drug conjugates (ADCs) aimed at treating solid tumors. Their mission is to create life-saving therapies through precision therapeutics. | $137M / Series B / Apr 08, 2026 | |
Mediar Therapeutics
|
Mediar Therapeutics is a biotechnology company that develops antibody-based medicines and biologic therapies to address cancer, autoimmune diseases, and other serious health conditions. Its research platform focuses on engineering multi-specific antibodies and modular biologics that can engage multiple biological targets or pathways simultaneously,enabling precise modulation of immune responses. The company’s pipeline includes therapeutic candidates designed to activate or inhibit specific immune functions, with the goal of improving clinical outcomes in oncology and immune-mediated disorders. Mediar Therapeutics also works on scalable manufacturing processes and collaborates with scientific partners to advance its biologics from discovery through clinical development. Its approach integrates protein engineering, immunology, and translational research to create biologic medicines that address complex disease mechanisms. The company continues to refine its technology and expand its therapeutic programs to support future clinical and regulatory progress. | $76M / Series B / Jan 07, 2026 | |
AAVantgarde Bio
|
AAVantgarde Bio is developing gene therapies for inherited retinal disorders. | $141M / Series B / Nov 03, 2025 | |
Crystalys Therapeutics
|
Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout. | $205M / Series A / Sep 30, 2025 | |
Avenzo Therapeutics
|
Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment. | $60M / Series B / Sep 04, 2025 | |
Solu Therapeutics
|
Solu Therapeutics is a precision-medicine-focused company developing therapeutics to eliminate disease-driving cells. | $41M / Series A / Apr 09, 2025 | |
Newleos Therapeutics
|
Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines. | $93.5M / Series A / Feb 13, 2025 | |
|
Newleos Therapeutics
|
Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines. | $93.5M / Series A / Feb 13, 2025 | |
| See all 77 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Longwood Fund invest in?
Longwood Fund invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Series A and Series B stage. Most of the 77 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Longwood Fund's check size?
Longwood Fund typically joins rounds of $16M–$100M at Series A, $25M–$152M at Series B and $17M–$100M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Longwood Fund participates in.
How do I contact Longwood Fund?
Public channels for Longwood Fund include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Longwood Fund?
The team at Longwood Fund includes Aleks Radovic-Moreno (Partner), John McCabe (Operating Partner) and Christoph Westphal (Manager), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
